AstraZeneca’s Tagrisso) has been accepted for use as a monotherapy for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations in Scotland.
Copyright © 2024 | WordPress Theme by MH Themes